Autoimmunity in Retinitis Pigmentosa

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2007 by Semmelweis University.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Semmelweis University
ClinicalTrials.gov Identifier:
NCT00433277
First received: February 6, 2007
Last updated: February 8, 2007
Last verified: February 2007
  Purpose

Using local immune suppression, the trial seeks evidence for the hypothesis that autoimmunity plays a role in the pathomechanism of retinitis pigmentosa.


Condition Intervention
Retinitis Pigmentosa
Drug: twice-daily dosage with 0.5% cyclosporine-A eyedrops

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label

Resource links provided by NLM:


Further study details as provided by Semmelweis University:

  Eligibility

Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Clinical diagnosis of retinitis pigmentosa

Exclusion Criteria:

  • Cataract
  • Extremely low ERG wave amplitude (less than 8% of normal)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00433277

Locations
Hungary
Semmelweis University, Dept. of Ophthalmology
Budapest, Hungary, H-1085
Sponsors and Collaborators
Semmelweis University
Investigators
Study Director: Zoltán Z. Nagy, M.D. Semmelweis University, Dept. of Ophthalmology
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00433277     History of Changes
Other Study ID Numbers: KMolnar
Study First Received: February 6, 2007
Last Updated: February 8, 2007
Health Authority: Hungary: National Institute of Pharmacy

Additional relevant MeSH terms:
Retinitis
Retinitis Pigmentosa
Retinal Diseases
Eye Diseases
Eye Diseases, Hereditary
Retinal Dystrophies
Retinal Degeneration
Genetic Diseases, Inborn
Cyclosporins
Cyclosporine
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Therapeutic Uses
Dermatologic Agents
Antirheumatic Agents

ClinicalTrials.gov processed this record on April 15, 2014